Premium
Treatment of advanced neuroblastoma with i‐131 meta‐iodobenzylguanidine
Author(s) -
Garaventa Alberto,
De Bernardi Bruno,
Lanino Edoardo,
Guerra Paolo,
Bestagno Mario,
Bertolazzi Luigi,
Villavecchia Gian Paolo,
Claudiani Franco,
Arrighini Alberto
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910215)67:4<922::aid-cncr2820670411>3.0.co;2-d
Subject(s) - medicine , neuroblastoma , bone marrow , nuclear medicine , pediatrics , surgery , oncology , genetics , biology , cell culture
Abstract From February 1986 to December 1988, 31 children with advanced pretreated neuroblastoma were treated with 131‐I meta‐Iodobenzylguanidine (131‐MIBG). Thirteen children had been resistant to first‐line therapy, three had suffered a local relapse, and fourteen had suffered a disseminated relapse without overt bone marrow infiltration. One child was treated initially because of resistance to first‐line therapy, and subsequently for a local relapse. A total of 72 courses of 131‐MIBG was administered, with doses ranging from 2.8 to 6.0 GBq (median, 3.7 GBq). One child received five courses, two four courses, 13 three courses, four two courses, and 12 one course of 131‐MIBG. The most common toxic effect was thrombocytopenia, with a platelet level of less than 50,000/cmm occurring after 19 of 60 evaluable courses. A leukocyte count less than 1000/cmm was seen only once. There were six major responses (two complete) lasting 4 to 9 months, and two minor responses lasting longer than 38 and 44 months. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated who experienced disseminated relapse. Further studies of the role of 131‐I meta‐Iodobenzylguanidine in treatment of neuroblastoma are needed.